VolitionRx: Funding, Investors & Team (Sep 2026)
Volition is a worldwide life sciences organization creating straightforward, simple to utilize blood-based malignant growth tests to analyze a scope of diseases precisely. The tests depend on the study of Nucleosomics, which is the act of distinguishing and estimating nucleosomes in the circulation system or other natural liquid which means that illness is available. As disease screening programs become an ever increasing number of far and wide, its items mean to assist with diagnosing a scope of tumors rapidly, basically, precisely, and cost-really. Early analysis can possibly draw out the existence of patients as well as to work on their personal satisfaction. Volition's innovative work exercises are right now focused in Belgium, with extra workplaces in London, Texas, and Singapore, as the organization centers around putting up its demonstrative items for sale to the public first in Europe, then, at that point, in the U.S. furthermore, around the world.
VolitionRx has raised $40.8M across 6 funding rounds on record, the most recent an undisclosed round of $4.6M announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
VolitionRx Company Profile and Key Stats
Latest funding round on record: Jun 2026.
VolitionRx Funding Rounds
VolitionRx raised $6.0M in a Post-IPO Equity announced in Jul 2022.
7 months later, an undisclosed round of $8.7M was announced in Feb 2023.
4 months later, an undisclosed round of $16.5M was announced in Jun 2023.
6 months later, an undisclosed round of $2.7M was announced in Dec 2023.
2.3 years later, an undisclosed round of $2.3M was announced in Mar 2026.
3 months later, an undisclosed round of $4.6M was announced in Jun 2026.
VolitionRx Founders and Leadership Team
No contact details are on record for this team yet.
VolitionRx Funding Compared to Other Biotechnology Startups
VolitionRx's latest round of $4.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like VolitionRx in Biotechnology and Singapore
Companies Similar to VolitionRx
YouLabs is an early-stage, data-driven biotechnology and longevity technology company focused on shifting…
ImmunoScape is a company focused on immunomics, using a technology platform to analyze and characterize the…
Nuevocor, which has locations in both the United States and Singapore, is working on creating genetic…
Aevice Health Pte Ltd is a Singaporean company that originated from Nanyang Technological University and…
Mirxes is a biotech firm focused on uncovering, advancing, and providing precise preventive healthcare…
BioDefense introduces Bioshield, a product derived from edible ingredients designed to safeguard your food by…
Auristone delivers practical clinical insights through our epigenomics workflows, providing actionable…
ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in…
GDMC is a pharmaceutical organization that specializes in the production and development of genetic…
Meatiply, a company focused on food research, specializes in the creation and manufacturing of meat…
Empowering Healthier Meals by Harnessing the Best from Nature and Combining that our Knowledge of Food…
Automera dedicates itself to the creation of innovative therapeutic approaches for drug development.
VolitionRx Funding FAQs
What does VolitionRx do?
Volition is a worldwide life sciences organization creating straightforward, simple to utilize blood-based malignant growth tests to analyze a scope of diseases precisely. The tests depend on the study of Nucleosomics, which is the act of distinguishing and estimating nucleosomes in the circulation system or other natural liquid which means that illness is available. As disease screening programs become an ever increasing number of far and wide, its items mean to assist with diagnosing a scope of tumors rapidly, basically, precisely, and cost-really. Early analysis can possibly draw out the existence of patients as well as to work on their personal satisfaction. Volition's innovative work exercises are right now focused in Belgium, with extra workplaces in London, Texas, and Singapore, as the organization centers around putting up its demonstrative items for sale to the public first in Europe, then, at that point, in the U.S. furthermore, around the world.
How much funding has VolitionRx raised?
VolitionRx has raised $40.8M across 6 rounds on record. The most recent is an undisclosed round of $4.6M announced in Jun 2026.
When did VolitionRx last raise funding?
VolitionRx's most recent funding round on record is an undisclosed round of $4.6M, announced in Jun 2026.
Who founded VolitionRx?
FundedIQ lists Jasmine K (Founder), Remi Rabeuf (Founder), Terry Kelly (Founder) at VolitionRx.
Who is the CEO of VolitionRx?
Cameron Reynolds is listed as CEO at VolitionRx.
Where is VolitionRx headquartered?
VolitionRx is based in Singapore, Central Region, Singapore.
How many employees does VolitionRx have?
VolitionRx is in the 11-50 employee band.
How does VolitionRx's funding compare to other Biotechnology startups?
VolitionRx's latest round of $4.6M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's VolitionRx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for VolitionRx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.